Ulodesine. Purine nucleoside phosphorylase inhibitor, treatment of gout

Drugs of the Future

Volumn 39, Issue 2, 2014, Pages 123-128

  Gras, J ^a  

^a NONE

Author keywords

Arthritis; BCX 4208; Gout; Metabolic syndrome; Ulodesine

Indexed keywords

ALLOPURINOL; HYPOXANTHINE; ULODESINE; URIC ACID; XANTHINE;

ADD ON THERAPY; ARTICLE; CLINICAL TRIAL (TOPIC); DRUG EFFICACY; DRUG INDICATION; DRUG METABOLISM; DRUG SAFETY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TOLERABILITY; ENZYMATIC ASSAY; GOUT; HUMAN; IN VITRO STUDY; NONHUMAN; PHARMACODYNAMICS; URIC ACID BLOOD LEVEL;

EID: 84930537950     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2014.039.02.2111643     Document Type: Article

References (30)

1. Bradley, P.A., de Koning, P.D., Johnson, P.S., Lecouturier, Y.C., McManus, D.J., Robin, A., Underwood, T.J. Development of a practical synthesis of the progesterone receptor antagonist 4-[[3-cyclopropyl-1(mesylmethyl)-5- methyl-1H-pyrazol-4-yl]oxy]-2,6-dimethylbenzonitrile. Org Process Res Dev 2009, 13(5): 848.
2. Evans, G.B., Furneaux, R.H., Tyler, P.C., Schramm, V.L. Synthesis of a transition state analogue inhibitor of purine nucleoside phosphorylate via the Mannich reaction. Org Lett 2003, 5(20): 3639-40. (Pubitemid 37289543)
3. Evans, G.B., Tyler, P.C. (Callaghan Innovation Research, Ltd.; Albert Einstein College of Medicine). Process for preparing inhibitors of nucleoside phosphorylase and nucleosidases. JP 2006516615, US 7655795, US 2010094003, WO 2004069856.
4. Furneaux, R.H., Schramm, V.L., Lenz, D.H., Evans, G.B., Tyler, P.C., Zubkova, O.V. (Albert Einstein College of Medicine; Callaghan Innovation Research, Ltd.). Inhibitors of nucleoside phosphorylases and nucleosidases. CA 2496698, EP 1539783, JP 2006501239, US 2006160765, US 2009239885, US 8173662, WO 2004018496.
5. Evans, G.B., Furneaux, R.H., Lewandowicz, A., Schramm, V.L., Tyler, P.C. Synthesis of second-generation transition state analogues of human purine nucleoside phosphorylase. J Med Chem 2003, 46(24): 5271-6. (Pubitemid 37414195)
6. Fast Facts. Gout(http://www.niams.nih.gov/Health-Info/Gout/gout-ff.pdf) (Accessed January 2, 2014).
7. Perez-Ruiz, F., Herrero-Beites, A.M. Evaluation and treatment of gout as a chronic disease. Adv Ther 2012, 29(11): 935-46.
8. Roddy, E., Mallen, C.D., Doherty, M. Gout. BMJ 2013, 347(7927): f5648.
9. Choi, H.K., Ford, E.S., Li, C., Curhan, G. Prevalence of the metabolic syndrome in patients with gout: The third national health and nutrition examination survey. Arthritis Rheum 2007, 57(1): 109-15.
10. Vitart, V., Rudan, I., Hayward, C. et al. SLC2A9 is a newly identified urate transporter influencing serum urate concentration, urate excretion and gout. Nat Genet 2008, 40(4): 437-42. (Pubitemid 351450879)
11. Roddy, E. Revisiting the pathogenesis of podagra: Why does gout target the foot? J Foot Ankle Res 2011, 4(1): 13.
12. Zhang, W., Doherty, M., Pascual, E. et al. EULAR Standing Committee for International Clinical Studies Including Therapeutics. EULAR evidence based recommendations for gout. Part I: Diagnosis. Report of a task force of the Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2006, 65(10): 1301-11. (Pubitemid 44641591)
13. Edwards, N.L. The role of hyperuricemia and gout in kidney and cardiovascular disease. Cleve Clin J Med 2008, 75(Suppl. 5): S13-6.
14. Zhang, W., Doherty, M., Pascual, E. et al. EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2006, 65(10): 1312-24. (Pubitemid 44620440)
15. Khanna, D., FitzGerald, J.D., Khanna, P.P. et al. 2012 American College of Rheumatology Guidelines for management of gout Part I: Systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res 2012, 64(10): 1431-46.
16. Hamburger, M., Baraf, H.S., Adamson, T.C. et al. 2011 recommendations for the diagnosis and management of gout and hyperuricemia. Phys Sportsmed 2011, 39(4): 98-123.
17. Terkeltaub, R. Update on gout: New therapeutic strategies and options. Nat Rev Rheumatol 2010, 6(1): 30-8.
18. Ho, M.-C., Shi, W., Rinaldo-Matthis, A. et al. Four generations of transition-state analogues for human purine nucleoside phosphorylase. Proc Natl Acad Sci U S A 2010, 107(11): 4805-12.
19. Bantia, S., Parker, C., Upshaw, R. et al. Potent orally bioavailable purine nucleoside phosphorylase inhibitor BCX-4208 induces apoptosis in B- and T-lymphocytes - A novel treatment approach for autoimmune diseases, organ transplantation and hematologic malignancies. Int Immunopharmacol 2010, 10(7): 784-90.
20. Fitz-Patrick, D., Drummond, W., Pappas, J., Hollister, A. Effects of a purine nucleoside phosphorylase inhibitor, BCX4208, on the serum uric acid concentrations in patients with gout. Arthritis Rheum [Annu Sci Meet Am Coll Rheumatol/Assoc Rheumatol Health Professionals (ACR/ARHP) (Nov 6-11, Atlanta) 2010] 2010, 62(10, Suppl.): Abst 150.
21. Hollister, A., Becker, M., Terkeltaub, R., Waugh, A., Lyman, S., Flynt, A., Fitz-Patrick, D. BCX4208 shows synergistic reductions in serum uric acid in gout patients when combined with allopurinol. Annu Eur Congr Rheumatol (EULAR) (May 25-28, London) 2011, Abst THU0011.
22. Hollister, A.S., Becker, M.A., Terkeltaub, R., Waugh, A., Lyman, S., Flynt, A., Fitz-Patrick, D. BCX4208 synergistically lowers serum uric acid (sUA) levels when combined with allopurinol in patients with gout: Results of a phase 2 dose-ranging trial. Arthritis Rheum [Annu Sci Meet Am Coll Rheumatol/Assoc Rheumatol Health Professionals (ACR/ARHP) (Nov 4-9, Chicago) 2011] 2011, 63(10, Suppl.): Abst 1018.
23. Pearson, P.G., Bantia, S., Harman, L. Nonclinical drug-drug interaction profile of BCX4208, an oral, once-daily, novel nonmetabolized enzyme inhibitor for chronic management of gout. Arthritis Rheum [Annu Sci Meet Am Coll Rheumatol/Assoc Rheumatol Health Professionals (ACR/ARHP) (Nov 4-9, Chicago) 2011] 2011, 63(10, Suppl.): Abst 1026.
24. Bantia, S., Harman, L., Hollister, A., Pearson, P. BCX4208, a novel enzyme inhibitor for chronic management of gout shows a low risk of potential drug-drug interactions. Annu Eur Congr Rheumatol (EULAR) (June 6-9, Berlin) 2012, Abst FRI0401.
25. Becker, M., Hollister, A., Terkeltaub, R., Waugh, A., Flynt, A., Fitz-Patrick, D., Sheridan, W. BCX4208 added to allopurinol increases response rates in patients with gout who fail to reach goal range serum uric acid on allopurinol alone: A randomized, double-blind, placebo-controlled trial. Annu Eur Congr Rheumatol (EULAR) (June 6-9, Berlin) 2012, Abst FRI0367.
26. Becker, M.A., Hollister, A.S., Terkeltaub, R. et al. BCX4208 combined with allopurinol increases response rates in patients with gout who fail to reach goal range serum urate on allopurinol alone: A randomized, double-blind, placebo-controlled trial. Arthritis Rheum [Annu Sci Meet Am Coll Rheumatol/Assoc Rheumatol Health Professionals (ACR/ARHP) (Nov 4-9, Chicago) 2011] 2011, 63(12): Abst L10.
27. Bantia, S., Parker, C., Harman, L., Papac, D., Hollister, A.S. Effect of BCX4208 add-on therapy to allopurinol 300 mg on plasma hypoxanthine and xanthine concentrations in gout patients. Annu Eur Congr Rheumatol (EULAR) (June 6-9, Berlin) 2012, Abst OP0106.
28. Bantia, S., Harman, L., Parker, C., Papac, D., Maetzel, A., Taubenheim, B., Hollister, A.S. Effect of BCX4208 (ulodesine) add-on therapy to allopurinol 300 mg on plasma hypoxanthine and xanthine concentrations in gout patients. 76th Annu Sci Meet Am Coll Rheumatol (Nov 9-14, Washington, D.C.) 2012, Abst 1633.
29. Hollister, A., Dobo, S., Maetzel, A. et al. Long-term safety of BCX4208 added to allopurinol in the chronic management of gout: Results of a phase 2 24-week blinded safety extension and vaccine challenge study. Annu Eur Congr Rheumatol (EULAR) (June 6-9, Berlin) 2012, Abst FRI0380.
30. Hollister, A., Maetzel, A., Becker, M., Terkeltaub, R., Fitz-Patrick, D., Smith, V., Sheridan, W.P. Ulodesine (BCX4208) long-term safety when added to allopurinol in the chronic management of gout: A phase 2 randomized controlled trial with 24-week blinded safety extension and vaccine challenge study. 76 th Annu Sci Meet Am Coll Rheumatol (Nov 9-14, Washington, D.C.) 2012, Abst 150.